Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

Aurinia Pharmaceuticals' (AUPH) Price Target Raised to $10 at H.C. WainwrightAugust 17, 2016 9:00 AM Aurinia Pharmaceuticals's (AUPH) Outperform Rating Reiterated at FBR Following AURA-LV Phase IIb DataAugust 15, 2016 10:58 AM Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus NephritisAugust 15, 2016 6:00 AM